

Details: One award will be presented. Candidates may be nominated by their mentors, colleagues, or may self-nominate. Details are provided below.
Name: | Dr. Ralph Meyer Phase III Young Investigator Award |
Description | The Ralph Meyer Young Investigator Award is presented annually to any MD, fellow, PhD within 10 years of certification / first faculty appointment or current fellow who has either spent time at CCTG Central Office, worked on Phase III projects with Disease Site Committees / Endpoint Committees / Working Groups, or who has contributed significantly to the conduct of a Phase III trial at a centre. |
Awarded: | Annually at the CCTG Annual Spring Meeting of Participants |
Eligible: | Any MD, fellow, PhD, within 10 years of certification / first faculty appointment or current fellow who has either spent time at Central Office (i.e. fellows), worked on Phase III projects with Disease Site Committees / Endpoint Committees / Working Groups, or who has contributed significantly to the conduct of a Phase III trial at a centre. |
Selection: | All CCTG Investigators and Central Office Senior Investigators and Management will be asked to nominate potential awardees. A letter of nomination and support (or scientific abstract) is requested to facilitate the selection. The CCTG Clinical Trials Committee will review and select one awardee. |
Award: | Glass Award. |
Nomination Process:
- Provide an abstract submitted to another meeting (e.g. ASCO, AACR) during 2020 or 2021 that meets the criteria listed above AND a brief cover letter describing the nominee’s background; OR
- Submit a letter detailing the nominee’s background and achievements, involvement in the activities/trials of the Phase III Program in 2020/2021, and why he/she is a candidate for the award.
Deadline: March 5, 2021.
Please submit all nominations to Heather Stanton, at hstanton@ctg.queensu.ca on behalf of the CCTG Director, Dr. Janet Dancey.
2020 Award Winner

Dr. Dan Renouf
Dr. Daniel Renouf is a medical oncologist at BC Cancer, Vancouver Centre, and an Associate Professor at the University of British Columbia, Department of Medicine. He received his Doctor of Medicine from the University of Alberta and completed his internal medicine and medical oncology training at the University of British Columbia and BC Cancer. He undertook further training in early drug development and gastrointestinal oncology at Princess Margaret Cancer Centre and the University of Toronto, and obtained a Masters of Public Health from Harvard University. Daniel’s research interests include developmental therapeutics, genomics, and biomarker development within gastrointestinal cancers, with a focus on pancreatic cancer. He is the leader of the BC Cancer Phase I program, the BC Cancer GI Tumour Group chair, the Co-Director of Pancreas Centre BC and is the Co-chair of the Canadian Cancer Trials Group Pancreatic Cancer disease group.
2019 Award Winner

Dr. Srinivas Raman
Dr. Srinivas Raman completed his medical school at University of British Columbia and his radiation oncology residency at University of Toronto. During his residency, he worked with Dr. Edward Chow and the CCTG Quality of Life Committee to perform secondary analyses on the SC.20 and SC.23 trials. His research validates the use of the EORTC QLQ-BM22 questionnaire in patients with bone metastases and informs the interpretation of score changes in the QLQ-BM22 and QLQ-C15-PAL/QLQ-C30 instruments. He won the Multinational Association of Supportive Care in Cancer 2016 Young Investigator Award for these research efforts. He is currently a radiation oncology fellow at BC Cancer Vancouver. He is working with Dr. Alan Nichol, the HN6 trial team and the CCTG Quality Assurance committee to develop methodology to individualize and automate radiotherapy quality assurance in clinical trials; he received the 2018 Canadian Association of Radiation Oncology fellowship award for this research proposal. His clinical sites of interest include central nervous system, lung and genitourinary malignancies. His research efforts are currently focused on radiotherapy quality assurance and machine learning applications in oncology.
2018 Award Winner

Dr. Alysa Fairchild
Dr. Fairchild graduated with a Bachelor of Science from McGill University in Montreal and obtained her MD from Queen’s University in Kingston. She began residency in radiation oncology at the Tom Baker Cancer Centre in Calgary and completed her training at the Cross Cancer Institute in Edmonton. After receiving FRCPC certification in 2006 and completing a one-year clinical / research fellowship at the Cross, she received her first faculty appointment at the University of Alberta in 2007. She took a sabbatical from practice to complete an additional fellowship year in Brussels, as the first North American EORTC Fellow in Quality Assurance in Radiation Oncology. She is currently Associate Professor at the University of Alberta specializing in treating lung and gastrointestinal malignancies, and is a member of the clinical treatment team of the Advanced Imaging and Gamma Knife Centre, University of Alberta Hospital. Her research is focused in the areas of radiotherapy QA within cooperative group trials, palliative radiation, supportive care, and patient-reported outcomes. She was the Canadian Co-Chair of SC.23, and is a member of CCTG’s Data Safety Monitoring Committee and Radiation Oncology Quality Assurance Committee. She is a trial committee member and local site PI of HE.1.
2018 Award Winner

Dr. Winson Cheung
Dr. Cheung is a medical oncologist and a nationally and internationally recognized cancer health services researcher. From 2010 to 2016, he worked in Vancouver at BC Cancer. In 2017, he was recruited to Alberta, where he is currently an Associate Professor of Medicine in the Department of Oncology at the University of Calgary and the Provincial Director of Health Services Research for Cancer Control Alberta. Dr. Cheung received his medical degree at the University of British Columbia, medical oncology subspecialty training at the University of Toronto and subsequently obtained a Master of Public Health degree at Harvard University. He is a prior Chair of the ASCO Health Services Research Scientific Program Committee. Having published over 120 peer-reviewed scientific manuscripts, he is the recipient of numerous accolades for his real-world studies in oncology and has secured over $5 million in research grant funding as a Principal Investigator. He continues to contribute to the Canadian Cancer Trials Group by serving on its Economic Analysis Committee and Quality of Life Committee.
2017 Award Winner

Dr. Tanya Skamene
Dr. Skamene is a medical oncology fellow at McGill University. She completed her MD (in 2010), internal medicine and hematology training (in 2015) at McGill University, followed by a 12-month clinical trials fellowship focusing on the design and conduct of phase II/III clinical trials at the Canadian Cancer Trials Group. During her fellowship, she completed a secondary analysis of the LY.12 randomized clinical trial evaluating outcomes of patients with peripheral T-cell lymphoma, which has been accepted for publication in Leukemia & Lymphoma. In addition, she received the John H. Crookston award by the Canadian Hematology Society and an American Society of Hematology Abstract achievement award in 2016 for her project on wait times for autologous stem cell transplantation in relapsed or refractory lymphoma. Her clinical area of interest is in hematologic malignancies and geriatric oncology.
2016 Award Winner

Dr. Patricia Tang
Dr. Tang is a medical oncologist at the Tom Baker Cancer Centre. She completed her MD with Distinction and Honors in Research at the University of Alberta, oncology training at the University of Calgary, followed by an 18-month drug development fellowship focusing on design of early phase clinical trials and biomarker development at the Princess Margaret Cancer Centre, University of Toronto. She was awarded an ASCO Young Investigator Award in 2007. Currently, she is the Southern Alberta Gastrointestinal Tumor Group Leader, the Alberta Representative to 3CTN, as well as the Centre Representative for the
2015 Award Winner

Dr. Matthew Cheung
Dr. Cheung obtained his Medical Degree (1999) and also completed residency programs in Internal Medicine and Hematology (1999-2004) at the University of Toronto. In 2006, he obtained a Masters degree in Clinical Epidemiology at the Harvard School of Public Health in Boston. Dr. Cheung is currently on staff at Sunnybrook Health Sciences Centre as a Clinician-Investigator and Clinical Hematologist. He is an Assistant Professor in the Department of Medicine at the University of Toronto. He serves on the Hematology Disease Site Executive Committee for the Canadian Cancer Trials Group, the Committee for Economic Analysis, and is Co-Chair of the Hematology Cancer Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. His research interests include pharmacoeconomic evaluation in hematologic malignancies, clinical trials in lymphoma and AIDS-related malignancies.
2014 Award Winner

Dr. Annette Hay
Details: One award will be presented. Candidates may be nominated by their mentors, colleagues, or may self nominate. Details are provided below.
Name: | Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award |
Description | The Elizabeth Eisenhauer Young Investigator Award is presented annually to any MD, fellow, or PhD, within 7 years of certification / first faculty appointment, or current fellow who has either spent time at CCTG Central Office, worked on projects with the Investigational New Drug (IND) Program or who has contributed significantly to the conduct of an IND trial at a centre. |
Awarded: | Annually at the CCTG Annual Spring Meeting of Participants |
Eligible: | Any MD, fellow, PhD, within 7 years of certification / first faculty appointment or current fellow who has either spent time at Central Office (i.e fellows), worked on projects with IND (e.g. database reviews) or who has contributed significantly to the conduct of an IND trial at a centre. |
Selection: | All IND Investigators and Central Office Senior Investigators and Management will be asked to nominate potential awardees and a 1-page letter of nomination and support (or scientific abstract) will be requested. The IND Executive Committee will review and select one awardee. |
Award: | Glass Award and opportunity to present their work at the IND Open Meeting at the CCTG Annual Spring Meeting of Participants. |
Nomination Process:
- Provide an abstract submitted to another meeting (e.g. ASCO, AACR) during 2020 or 2021 that meets the criteria listed above with regards to IND Program involvement AND a brief cover letter describing the nominee’s background and achievements; OR
- Submit a letter detailing the nominee’s background and achievements, involvement in the activities/trials of the IND Program in 2020/2021, and why he/she is a candidate for the award.
Deadline: March 5, 2021.
Please submit all nominations to Heather Stanton, at hstanton@ctg.queensu.ca on behalf of the IND Director, Dr. Lesley Seymour.
2020 Award Winner

Dr. Sara Taylor
2019 Award Winner

Dr. Alexander Wyatt
2018 Award Winner

Dr. John Hilton
2017 Award Winner

David Cescon
2016 Award Winner

Dr. Rachel Goodwin
2016 Award Winner

Dr. Marshall Pitz
2015 Award Winner

Dr. Penny Bradbury
2014 Award Winner

Dr. Daniel Renouf
2013 Award Winner

Dr. Jose Monzon
Details: One award will be presented. Candidates may be nominated by their mentors or colleagues. Details are provided below.
Name: | Dr. Joseph Pater Excellence in Clinical Trials Research Award |
Description | The Founder's Award is presented annually to an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This award honours an Investigator whose excellence in clinical trials research has provided techniques, information or concepts that will direct the future of the oncology research community and the Canadian Cancer Trials Group (CCTG). |
Awarded: | Annually at the CCTG Annual Spring Meeting of Participants |
Eligible: | Any CCTG Investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This award honours an Investigator whose excellence in clinical trials research has provided techniques, information or concepts that will direct the future of the oncology research community and the CCTG. |
Selection: | All CCTG Investigators and Central Office Senior Investigators and Management will be asked to nominate potential awardees. A letter of nomination and support is requested to facilitate the selection. The CCTG Trials Committee will review and select one awardee. |
Award: | Glass Award |
Nomination Process:
- Submit a letter detailing the nominee’s background, achievements, involvement in CCTG activities and trials, as well as why the nominee is an appropriate candidate for the award. Abstract(s) may also be submitted in support of the nomination
Deadline: March 5, 2021.
Please submit all nominations to Heather Stanton at hstanton@ctg.queensu.ca on behalf of the CCTG Director, Dr. Janet Dancey.
2020 Award Winner

Dr. Tim Whelan
Dr. Whelan’s research has focused on health services research and clinical trials in radiation oncology. Throughout his career he has focused on conducting rigorous clinical trials to test new treatment strategies and technologies to guide the local treatment of breast cancer. He led one of the first trials comparing a short hypofractionated 3-week regimen of radiation compared to the then conventional 5-week treatment for local breast irradiation after breast conserving surgery. The shorter regimen was shown to be equally effective with no increased toxicity and has been widely used across Canada. He also led the CCTG MA.20 trial, which showed that the addition of regional nodal irradiation to whole breast irradiation after breast conserving surgery reduced the risk of breast cancer recurrence, both locally and distantly leading to the wide adoption of this approach for women with node positive breast cancer.
In recent years, Dr. Whelan has extended his research to evaluate the ability of biomarkers to predict the risk of local recurrence and effectiveness of radiation in early breast cancer. He has established a network of investigators across Canada and trained a number of radiation oncologists interested in studying the optimal treatment of women with breast cancer.
2019 Award Winner

Dr. Derek Jonker
2018 Award Winner

Dr. J. Gregory Cairncross
Dr. Cairncoss is best known for his contributions to the understanding oligodendrogliomas. He and David Macdonald observed their unique sensitivity to chemotherapy, and he and David Louis demonstrated that co-deletion of chromosomes 1p and 19q is a molecular marker of chemosensitivity and long survival in this cancer. With the RTOG and CCTG, he led the North American randomized clinical trial that confirmed these findings. Co-deletion of 1p/19q is now a cornerstone of the molecular classification of gliomas and testing for this biomarker is used worldwide to diagnose and manage patients with this type of brain cancer. Recently, he led the Terry Fox Research Institute translational program project on “Therapeutic Targeting of GBM’.
He has written extensively on glioma biology and therapy and is a member of the Royal Society of Canada.
2017 Award Winner

Ming-Sound Tsao
2016 Award Winner

Dr. Kathleen Pritchard
2015 Award Winner

Dr. Michael Brundage
2015 Award Winner

Dr. Frances Shepherd
2014 Award Winner

Dr. Vivien Bramwell
Details Metrics regarding trial-specific accrual both overall and for 2020, local activation timelines, and also compliance metrics are compiled by Central Office. From there, this information will be reviewed by the Executive Investigational New Drug (IND) Committee for the IND Team Award and by the Clinical Trials Committee for Phase III Trial Team Awards. Individual Trial Teams from member centres will be acknowledged for their efforts and dedication to the success of clinical trials. No external nomination process. Trial Team awardees will be announced at the CCTG Annual Spring Meeting of Participants.
Questions and feedback regarding Trial Team Awards can be directed to Heather Stanton, at hstanton@ctg.queensu.ca.
2020 Award Winner

Investigational New Drug Program Team Award
BCCA Vancouver Centre (CAVA) IND.234 Trial Team
TThe team members include: Kim Chi, Manahil Sadiq, Julita Sienkiewicz, and Wendy Won.
2020 Award Winner

Phase III Program Team Award
Saskatoon Cancer Centre (CASS) MAC.21 Trial Team
The team members include: Nayyer Iqbal, Osama Ahmed, Shahid Ahmed, Tehmina Asif, Kamal Haider, Amer Sami, Mita Manna, Andrea Gallivan, Dominique Wagner, Jolene Hicks.
2020 Award Winner

Phase III Program Team Award
Princess Margaret Cancer Centre (CAMP) CE.8 Trial Team
The team members include: Warren Mason, Normand J. Laperriere, Barbara Ann Millar, David Shultz, Derek Tsang, Ronald Ramos, Seth Climans, Stephanie Baker, On Yee Jones, Lynette Francis, Risho Yogananthan, Stephanie DeLuca, Anjie Yang, Irum Mahmood, Divyalakshmi Babu, Christina Cater, Kristin Dunlop, Sarah Eley, Shirley Ho, Sam Park, Rosa Pezzulli, Eamay Apostol, Moya Brown, Chermay Espino, Jermain Joseph, Hema Mohabir, Kenneth Mojica, Madeline Philips, Kathie Witkowski, Jessy Abed, Benoit Guibord, Vanessa Speers, Nanthini Tharahan, Rohini Gosai
2020 Award Winner

Phase III Program Team Award
Princess Margaret Cancer Centre (CAMP) HN.10 Trial Team
The team members include: Scott Bratman, Andrew Bayley, John Cho, Meredith Giuliani, Ezra Hahn, Andrew Hope, Ali Hosni, John Kim, Jolie Ringash, John Waldron, Aaron Hansen, Lillian Siu Anna Spreafico, John de Almeida, Eugene Yu, Ur Metser, Pat Merante, Masoud Mohammadi Andrei Rotarescu, Rehab Chahin, Jesse Abed, Maria Braganza, Zoe Doyle, Sarah Ramotar, and Vanessa Speers
2019 Award Winner

Investigational New Drug Program Team Award
IND.227 Team - Centre hospitalier de l’Université de Montréal
Alexandra Frazzi, Fernanda Janeiro, Valérie Brulotte, Audrey Lavigne, Bertrand Routy, Marie Florescu, Jean-Pierre Ayoub, Anick Lambert, Mustapha Tehfé, Marie-Pier Jalbert Gariépy, Normand Blais
2019 Award Winner

Investigational New Drug Program Team Award
IND.234 Team - Centre hospitalier de l’Université de Montréal
Amal Nadiri, Brigitte Brisson, Virginie Decamps, Vikie Lamontagne, Lyndsey Kirwan, Any Tétreault, Chantal Plantanoff, Cynthia Levesque, Olga Guerra, Cynthia Girard-Roc, Lyne Girard, Fred Saad
2019 Award Winner

Phase III Program Team Award
PM.1 Team - Princess Margaret Cancer Centre
Vicky Gillman, Nanthini Tharahan, Eoghan Malone, Sevan Hakgor, Amanda Giesler, Thenushi Jayasinghe, Jeffrey Doi, Celeste Yu, Vanessa Speers, Philippe Bedard, Tracy Stockley, Stephanie Lheureux, Trevor Pugh, Kelsey Zhu, Lillian Siu
2019 Award Winner

Phase III Program Team Award
MAC.22 Team - Ottawa Hospital Research Institute
Jean Seely, Raman Verma, Betty Anne Schwarz, Holly English, Luisa Ianni, Myka Caluyong, Kelly Villeneuve, Carolle Anderson, Christie Barbesin, Marzanna Bednarek-Zilinskas, Sharlene Bilmer, Annik Blanchette, Erin Fowlie, Sylvie Lachance, Pernille Lamontagne, Gary Heddon, Ian Byrne
2018 Award Winner

Investigational New Drug Program Team Award
IND.227 Team - Cross Cancer Institute, Edmonton
Pinky Matthew, Romeo Felix, Jennifer Paulino, Carole Gallagher, Quincy Chu, Michael Smylie, Naveen Basappa, Nirmal Joshi, Beverly Larson, Usha Kumar, Elizabeth Gaetz, Charles Butts, Randeep Sangha, Anil Joy
2018 Award Winner

Investigational New Drug Program Team Award
IND.227 Team - NCI Naples Clinical Trials Unit, Italy
Maria Carmela Piccirillo, Jane Bryce, Lucia Sparavigna, Federka Crudele, Maria Teresa Ribecco, Giuliana Canzanella, Clorinda Schettino, Marilena Martino, Fiorella Romano, Giovanni De Matteis, Manuela Florio, Anna Gimigliano, Simona Bevilacqua, Francesco Perrone, Cesare Gridelli, Saverio Cinieri, Fortunato Ciardiello, Alessandro Morabito, Fabiana Cecere, Federica Grosso, Maria Pagano, Marco Angelo Burgio, Marina Garassino, Luigi Cavanna, Manlio Mencoboni, Gennaro Daniele, Allfonso Savio, Antonia Del Giudice
2018 Award Winner

Phase III Program Team Award
PA.7 Team BCCA – Vancouver Cancer Centre
Gillian Erickson, Vivian Alie, Fran Topp, Carolyn Hoeschen, Janelle Bellerive, Kate Hart, Suilee Quach, Naghmeh Esmaeili, Sharlene Gill, Howard Lim, Janine Davies, Malcolm Moore, Daniel Renouf
2018 Award Winner

Phase III Program Team Award
MEC.5 Team Juravinski Cancer Centre Hamilton
Robin Eady, Theresa Stokes, Janet Barclay, Diane Derosa, Anne Laughlin, Shirley-Ann Hahn, Helen Shing, Amanda Boyes, Elisa Shore, Christine Ballantyne, Bianca Bier, Yvonne Kinrade, Elaine Hill, Ing Collins, Leah Cox, Amanda Dam, Jeanette Van Norden, Richard Tozer, Sebastien Hotte, Rosalyn Juergens, Elaine McWhirter
2017 Award Winner

Investigational New Drug Program Team Award
IND.226 Team - Ottawa Hospital Research Institute
Caroline Lalonde, Deborah Keller, Nancy Drummond-Ivars, Sopear Tep, Saren Roeun, Kathy Lebreux, Natascha Parisien, Caroline Dean, Maria Lalonde, Louiselle Godbout, Lise Thaw, Alison Sutherland, Lena McAleer, Emma Webster, Femina Kanji, Elina Iordanidi, Lisa MacMullin, Jennifer Knudson, Sharon Kelly, Marie-Claude Reeves
2017 Award Winner

Investigational New Drug Program Team Award
IND.214 Team - Ottawa Hospital Research Institute
Julie Wells, Saara Ali, Kaitlyn Chambers, Sara Richardson, Kathy Lebreux, Natascha Parisien, Caroline Dean, Maria Lalonde, Louiselle Godbout, Lise Thaw, Alison Sutherland, Lena McAleer, Emma Webster, Lisa Turriff, Amy Henderson, Elina Iordanidi, Lisa MacMullin, Ruth Simpson, Sharon Kelly, Marie-Claude Reeves
2017 Award Winner

Phase III Program Team Award
PR.17 Team - Cross Cancer Institute, Edmonton
Scott North, Naveen Basappa, Michael Kolinsky, Carlie Smith, Beverly Larson, Monika Lang, Leni Santiago Garcia, Margo Miller, Daphne Willan, Nirmal Joshi, Candra Williams
2017 Award Winner

Phase III Program Team Award
SC.24 Team - Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto
Arjun Saghal, Lori Holden, Delareese Mackenzie, Maurice Zakhem, Marko Cadonic, Joe Presutti, Collins Yeboah, Mark Ruschin, Brige Chugh, Mikki Campbell, Young Lee, Sten Myrehaug, Eric Tseng, Michelle Gianotti, Elizabeth Lui, Hany Soliman, Hyla Okorofsky
2016 Award Winner

Investigational New Drug Program Team Award
IND.226 Team Juravinski Cancer Centre at Hamilton Health Sciences
Andrew Arnold, Denise Charbonneau, Ing Collins, Kathy Cowan, Diane DeRosa, Robin Eady, Peter Ellis, John Goffin, Shirley-Ann Hahn, Hal Hirte, Sebastien Hotte, Rosalyn Juergens, Yvonne Kinrade, Brenda Kowaleski, Anne Laughlin, Elaine McWhirter, Elisa Shore, Jeanette Van Norden
2016 Award Winner

Investigational New Drug Program Team Award
IND.226 Team Tom Baker Cancer Centre, Calgary
Aaron Baumgarten, Gwyn Bebb, Florizel Bernardo, Anna Giulione, Desiree Hao, Lydian Hare, Klara Lavoie, Michelle Mills
2016 Award Winner

Phase III Program Team Award
CO.21 Team Cross Cancer Institute, Edmonton
Neil Chua, Anthony Fields, Amelie Fontaine, Leni Santiago Garcia, Julie Price Hiller, Maria Ho, Karen King, Sheryl Koski, Monika Lang, Beverly Larson, Karen Mulder, Michael Sawyer, Carlie Smith, Andrew Scarfe, Jennifer Spratlin, Candra Williams, Xiaofu Zhu
2016 Award Winner

Phase III Program Team Award
MAC.15 Team BCCA, Vancouver Cancer Centre
Eden Blumenauer, Cheryl Carrasco, Adelaide Dede, Janice Pope, Rosanne Serpanchy, Wendy Won, Carleen Yu
2015 Award Winner

Investigational New Drug Program Team Award
IND.211 and IND.215 Teams Ottawa Hospital Research Institute
Kendra Christink, Michelle McWilliam, Matt Fish, Lisa Turriff, Amy Henderson, Lisa MacMullin, Femina Kanji, Nancy Drummond-Ivars, Kathy Lebreux, Maria Lalonde, Lise Thaw, Ruth Simpson, Lena McAleer, Emma Webster, Sharon Kelly, Garth Nicholas
2015 Award Winner

Phase III Program Team Award
NEC.3 Team Dr. Léon-Richard Oncology Centre
Gisèle Bernard, Bernise Gaudet, Karine Morin, Joanne Rockburn, Brigitte Sonier-Ferguson, Nicholas Finn, Ali Benjelloun, Skander Ghedira, Eve St-Hilaire, Pierre Whitlock, Nancy Hallé & Pharmacy Team
2015 Award Winner

Phase III Program Team Award
BL.12 Team Princess Margaret Cancer Centre
Jill Sheedy, Mary Beth Zavitz, Laurie Adams, Soo Chin, Maria Schlag, Nanthini Tharahan, Leslie Duncan & Pharmacy Team, Vanessa Speers & Correlative Team, Sujata Pokhrel, Anna Malik, Srikala Sridhar, Jennifer Knox, Anthony Joshua, Aaron Hansen
2014 Award Winner

Investigational New Drug Program Team Award
IND.211 Team at CHUM Hôpital Notre-Dame
Isabelle Lacas, Mariejo Simard, Sarnia Jean-Baptiste
2014 Award Winner

Investigational New Drug Program Team Award
IND.210 Team at Ottawa Hospital Research Institute
Saara Ali, Carla Kinden, Deborah Keller, Diane Lister, Caryn Boheimer, Joanne Roach, Patti Spencer, Roxanne Ward, Lise Thaw, Lena McAleer, Maria Crutchley, Ruth Simpson, Emma Webster, Amy Henderson, Valerie Bourada, Mary Spearman, Lisa MacMullin, Nancy Drummond-Ivars, Kathy Lebreux, Maria Lalonde
2014 Award Winner

Phase III Program Team Award
MA.32 Vancouver Centre – BC Cancer Agency
Adelaide Dede, Rosanne Serpanchy, Wendy Won, Linda Wong. Sophie Sun, Karen Gelmon, PIs
2014 Award Winner

Phase III Program Team Award
BR.26 Princess Margaret Cancer Centre
Nicole Perera-Low, Nazanin Nouriany, Andrea Foster, Dianne Zawisza, Devalben Patel, Miriam Mirshams, Jeffrey Doi, Belling Leung, Kendra Ross, Vicky Gillman, Nashreen Leila, David Laurence, Kathryn Sabate, Maria Schlag, Fion Tang, Elham Absiye, Stephanie Zantinge, Cody Connolly, Vanessa Speers. Geoffrey Liu, PI
2013 Award Winner

Investigational New Drug Program Team Award
IND.205 Team at the British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre
The 2013 team award was presented to the IND.205 Team at the British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre -- Ms. Rongrong Karim, Mr. Shane Brown, and Mr. Wilfred Hui.